A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Autoimmune disorders; Inflammatory bowel diseases; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 11 Jan 2019 Status changed from recruiting to completed.
- 02 Aug 2018 Status changed from suspended to recruiting.
- 21 Mar 2018 Planned number of patients changed from 48 to 66.